Organization
Molecular Templates
4 clinical trials
1 abstract
Clinical trial
A Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients With Relapsed or Refractory Multiple MyelomaStatus: Terminated, Estimated PCD: 2023-12-13
Clinical trial
A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer TypesStatus: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid TumorsStatus: Terminated, Estimated PCD: 2023-02-01
Clinical trial
A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1Status: Recruiting, Estimated PCD: 2025-04-01
Abstract
MT-6402, an engineered toxin body (ETB) targeting PD-L1: Interim efficacy and safety data.Org: Mary Crowley Cancer Research Center, Washington University in Saint Louis, Brown Cancer Center, Sanford Cancer Center, Prisma Health Cancer Institute,